Merck Probed For Corrupt Foreign Practices
Merck has received letters from the US Department of Justice and the US Securities and Exchange Commission seeking information about "activities in a number of countries" with reference to the Foreign Corrupt Practices Act.
Merck has received letters from the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) seeking information about “activities in a number of countries” with reference to the Foreign Corrupt Practices Act. The Act makes it unlawful for US companies to bribe foreign government officials to obtain or retain business. Merck disclosed the information in a filing with the SEC and has said it is cooperating with the agencies and their requests.
Although the company has released no further details of the probe, third-party reports including The Wall Street Journal and Law360 claim that a spokesperson for Merck has said that it has not been charged for violating the Act and has a compliance programme in place to prevent such occurrences. On its website, Merck explains that it operates under a federal Corporate Integrity Agreement, which requires it to retain an independent review organisation to “conduct a systems review of its promotional policies and procedures and to conduct, on a sample basis, transactional reviews of Merck's promotional programs and certain Medicaid pricing calculations”. The company is also required to provide regular reports and certifications to the US Department of Health and Human Services Office of Inspector General regarding its compliance with the integrity agreement.
In the SEC filing, Merck also added that it believes the inquiry is “part of a broader review of pharmaceutical industry practices in foreign countries”. According to a report from Main Justice, the DOJ and the SEC have investigated several pharmaceutical companies for potential violations of the Foreign Corrupt Practices Act.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
